Welcome to the ACR Convergence 2024 Abstract Submission Site!
ACR Convergence 2024 is the world’s premier rheumatology meeting. The 2024 in-person meeting in Washington, DC, will offer scientific sessions, networking opportunities, and more. Join us in November for stellar rheumatology education, outstanding networking opportunities, and more.
The American College of Rheumatology (ACR) and the Association of Rheumatology Professionals (ARP) invite you to submit an abstract and take advantage of the opportunity to have your work peer reviewed by experts in the field. If accepted, your abstract will be published in an online supplement of the Arthritis & Rheumatology journal and displayed in the distinguished international venue of ACR Convergence 2024.
Please read the complete 2024 Call for Abstracts Guidelines prior to submitting.
New in 2024!
- The ACR will not offer CME credit for any abstract session or posters. Owners and employees of ACCME-defined ineligible companies may submit and present abstracts.
- New Poster Hall hours! Presenters are requested to be at their posters 10:30 AM – 12:30 PM.
- Our embargo policy has been updated. See relaxed restrictions on post-acceptance publication and presentation in the Abstract Embargo Policy
- Add Author Group information in step 8 of the “Additional Details” task.
Read the full instructions for Entering Institution Information to ensure your author block appears correctly
ACR Call for Abstracts
The ACR Convergence program includes content related to the clinical practice and teaching of rheumatology. Abstracts covering basic and translational science that contributes to the understanding of musculoskeletal and rheumatic disease pathogenesis, therapeutic mechanisms and efficacy, and studies investigating healthcare delivery to patients are eligible for submission.
The fee for submitting each abstract is $100. The ACR accepts electronic payment only in the form of MasterCard, Visa, or American Express. Abstract processing fees must be in U.S. funds. All fees are non-refundable—no exceptions. There are no refunds for rejected or withdrawn abstracts.
Submitters from countries with low-income and lower-middle-income economies as determined by the World Bank, for whom the abstract submission fee would cause undue hardship, may request that the abstract submission fee be waived. Please contact abstracts@rheumatology.org to provide proof of residency.
SUBMISSION DEADLINE: Thursday, June 18, 2024, noon Eastern Time—no exceptions. No changes may be made to your submission, including author information, after the deadline.
ARP Call for Abstracts
The ARP program reflects the needs and interests of healthcare professionals with an interest in rheumatology-related issues by offering a forum to address significant issues with a multidisciplinary audience. Abstracts will be peer reviewed by a subsection of the ARP Annual Meeting Program Subcommittee according to subject categories. ARP abstract sessions will not necessarily be scheduled by individual category.
A $50 processing fee accompanies each ARP abstract submission. The ARP accepts electronic payment only in the form of MasterCard, Visa, or American Express. Abstract processing fees must be in U.S. funds and are non-refundable—no exceptions. There are no refunds for rejected or withdrawn abstracts.
Submitters from countries with low-income and lower-middle-income economies as determined by the World Bank, for whom the abstract submission fee would cause undue hardship, may request that the abstract submission fee be waived. Please contact abstracts@rheumatology.org to provide proof of residency.
SUBMISSION DEADLINE: Thursday, June 18, 2024, noon Eastern Time—no exceptions. No changes may be made to your submission, including author information, after the deadline.
Abstract Eligibility
Persons Eligible to Submit
- Members and non-members of the ACR and ARP are eligible to submit an abstract.
- Employees or owners of ineligible companies may be the presenting author of an abstract. Abstract sessions do not have CME credit.
Abstracts Eligible for Submission
- Abstracts that have been previously accepted and/or presented at other medical meetings and published in conference proceedings (“encore” abstracts) are eligible for submission. These abstracts will go through the same peer review process as any other abstracts.
- Abstracts describing original basic and clinical science related to the broad area of rheumatic diseases may be submitted.
- Abstracts reporting results of a clinical trial will be required to identify the trial phase.
- Any work with human or animal subjects reported in submitted abstracts must comply with the guiding principles for experimental procedures found in the Declaration of Helsinki of the World Medical Association.
Abstracts Not Eligible for Submission
- Abstracts should not report results that have been previously presented at an ACR/ARP Annual Meeting.
- Abstracts that report work that has been accepted for publication as a manuscript (e.g., full-length article, brief report, case report, concise communication or letter to the editor, etc.) prior to the submission deadline of noon ET on Tuesday, June 18, 2024, are ineligible for consideration.
- Multiple abstracts may not be submitted for one study unless substantially different research questions are being addressed in each abstract.
- Abstracts submitted for the ARP program may not be concurrently submitted to the ACR program.
- Case reports are not considered appropriate and will not be reviewed. We encourage those with interesting cases or images to consider submission to the Thieves Market, Image Competition or Global Summit. See separate submission processes.
Thank you for your participation in ACR Convergence 2024. The ACR uses a single sign-on process that allows submitters to log into the submission site via their rheumatology.org account.
Browser Requirements: Google Chrome is the recommended browser for accessing the submission site. You may experience issues when using Firefox or Microsoft Edge.
Log in to the Abstract Site
Have a rheumatology.org account?
Click 'Login' to begin your submission.
Login